Abbott Laboratories Management
Management criteria checks 3/4
Abbott Laboratories' CEO is Robert Ford, appointed in Oct 2018, has a tenure of 6.92 years. total yearly compensation is $22.78M, comprised of 6.6% salary and 93.4% bonuses, including company stock and options. directly owns 0.026% of the company’s shares, worth $59.80M. The average tenure of the management team and the board of directors is 4.1 years and 6.6 years respectively.
Key information
Robert Ford
Chief executive officer
US$22.8m
Total compensation
| CEO salary percentage | 6.59% |
| CEO tenure | 6.9yrs |
| CEO ownership | 0.03% |
| Management average tenure | 4.1yrs |
| Board average tenure | 6.6yrs |
Recent management updates
Recent updates
Abbott Laboratories Q2 Earnings: Dividends Don't Lie
Aug 09Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices
Apr 16Abbott Laboratories Basking In A Sharp Turn In Sentiment
Mar 16Investors Shouldn't Be Too Comfortable With Abbott Laboratories' (NYSE:ABT) Earnings
Feb 28
Abbott Laboratories' (NYSE:ABT) Business Is Yet to Catch Up With Its Share Price
Feb 17Does Abbott Laboratories (NYSE:ABT) Deserve A Spot On Your Watchlist?
Feb 05Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)
Jan 23Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?
Jan 13Abbott Laboratories Q4 2024 Earnings Preview
Jan 08Abbott Laboratories: A Future-Driven Pharma Brand With A Robust Pipeline
Dec 21Calculating The Fair Value Of Abbott Laboratories (NYSE:ABT)
Dec 01Abbott Laboratories: Investors Should Wait For A Pullback
Nov 25Investors Will Want Abbott Laboratories' (NYSE:ABT) Growth In ROCE To Persist
Oct 31Abbott Laboratories: Long-Term Optimism, Short-Term Overvaluation
Oct 21Abbott: Challenging Comparables, Unappealing Value Limit The Incentive To Go Long Ahead Of Q3 Event
Oct 14Does Abbott Laboratories (NYSE:ABT) Have A Healthy Balance Sheet?
Oct 11Why We're Not Concerned About Abbott Laboratories' (NYSE:ABT) Share Price
Sep 27Abbott Laboratories: Cardiovascular Disease Has Been A Tailwind, But Things Could Change
Sep 11Abbott Laboratories: Driving Value By Scaling Innovations
Aug 13Abbott Laboratories: A Strong Healthcare Stock For Long-Term Dividend Growth Investors
Aug 05Abbott Laboratories: When Double-Digit Device Growth Apparently Isn't Enough
Jul 13Abbott Laboratories: Why I Agree With Wall Street On This One
Jun 04Abbott Laboratories: Buying More Of This Top-Notch Dividend Growth Stock
May 18CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2025 | n/a | n/a | US$14b |
| Mar 31 2025 | n/a | n/a | US$13b |
| Dec 31 2024 | US$23m | US$2m | US$13b |
| Sep 30 2024 | n/a | n/a | US$6b |
| Jun 30 2024 | n/a | n/a | US$6b |
| Mar 31 2024 | n/a | n/a | US$6b |
| Dec 31 2023 | US$23m | US$2m | US$6b |
| Sep 30 2023 | n/a | n/a | US$5b |
| Jun 30 2023 | n/a | n/a | US$5b |
| Mar 31 2023 | n/a | n/a | US$6b |
| Dec 31 2022 | US$22m | US$2m | US$7b |
| Sep 30 2022 | n/a | n/a | US$8b |
| Jun 30 2022 | n/a | n/a | US$9b |
| Mar 31 2022 | n/a | n/a | US$8b |
| Dec 31 2021 | US$25m | US$1m | US$7b |
| Sep 30 2021 | n/a | n/a | US$7b |
| Jun 30 2021 | n/a | n/a | US$6b |
| Mar 31 2021 | n/a | n/a | US$6b |
| Dec 31 2020 | US$20m | US$1m | US$4b |
| Sep 30 2020 | n/a | n/a | US$3b |
| Jun 30 2020 | n/a | n/a | US$3b |
| Mar 31 2020 | n/a | n/a | US$4b |
| Dec 31 2019 | US$12m | US$1m | US$4b |
| Sep 30 2019 | n/a | n/a | US$3b |
| Jun 30 2019 | n/a | n/a | US$3b |
| Mar 31 2019 | n/a | n/a | US$3b |
| Dec 31 2018 | US$8m | US$784k | US$2b |
Compensation vs Market: Robert's total compensation ($USD22.78M) is above average for companies of similar size in the US market ($USD13.61M).
Compensation vs Earnings: Robert's compensation has been consistent with company performance over the past year.
CEO
Robert Ford (51 yo)
Mr. Robert B. Ford has been the Chief Executive Officer of Abbott Laboratories since March 31, 2020 and also serves as its Chairman of the Board since December 10, 2021. He has been President at Abbott Lab...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 6.9yrs | US$22.78m | 0.026% $ 59.8m | |
| CFO & Executive VP of Finance | 2yrs | US$8.23m | 0.0029% $ 6.8m | |
| Executive VP and Group President of Established Pharmaceuticals & Nutritional Products | 11yrs | US$5.79m | 0.0077% $ 17.8m | |
| Executive VP & Group President of Medical Devices | 6.7yrs | US$6.56m | 0.0041% $ 9.5m | |
| Senior VP of Business & Technology Services and Chief Information Officer | 1.7yrs | no data | no data | |
| Vice President of Investor Relations. | no data | no data | no data | |
| VP and Chief Ethics & Compliance Officer | no data | no data | no data | |
| Executive VP | less than a year | no data | 0.0014% $ 3.3m | |
| Executive Vice President of Human Resources | 6.1yrs | no data | 0.0062% $ 14.2m | |
| Senior Vice President of Global Marketing & External Affairs | less than a year | no data | no data | |
| Executive Vice President of Nutritional Products | 8.7yrs | no data | no data | |
| Senior Vice President of Licensing | 2.2yrs | no data | no data |
Experienced Management: ABT's management team is considered experienced (4.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman of the Board | 5.8yrs | US$22.78m | 0.026% $ 59.8m | |
| Independent Director | 8.6yrs | US$350.89k | 0.39% $ 890.1m | |
| Independent Director | 8.7yrs | US$346.89k | 0.00020% $ 461.8k | |
| Lead Independent Director | 13.8yrs | US$395.89k | 0.00027% $ 623.4k | |
| Independent Director | 4.4yrs | US$340.89k | 0% $ 0 | |
| Independent Director | 16.9yrs | US$472.07k | 0% $ 0 | |
| Independent Director | 2.4yrs | US$325.89k | 0% $ 0 | |
| Independent Director | 7.3yrs | US$331.89k | 0.00018% $ 415.6k | |
| Independent Director | 13.8yrs | US$365.87k | 0% $ 0 | |
| Independent Director | 3yrs | US$356.89k | 0% $ 0 | |
| Independent Director | 6yrs | US$325.89k | 0% $ 0 | |
| Independent Director | 4.1yrs | US$356.89k | 0% $ 0 |
Experienced Board: ABT's board of directors are considered experienced (6.6 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/09/01 16:17 |
| End of Day Share Price | 2025/08/29 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Abbott Laboratories is covered by 66 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Stephan Gasteyger | Atlantic Equities LLP |
| Ishan Majumdar | Baptista Research |